Replies to post #224180 on Biotech Values

[DewDiligence]

ENTA is a sleeper entrant in the HBV arena. ENTA’s proven drug-discovery expertise in viral/liver diseases gives me confidence that their HBV core inhibitor will be a good one.

Among the new MoAs being tested by the various players are:

• Core-protein inhibition
• Capsid inhibition
• S-antigen inhibition
• RNA degradation